002773 康弘药业
已收盘 05-29 15:00:00
资讯
新帖
简况
康弘药业：KH631、KH658已完Ⅱ期和Ⅰ期入组
证券之星 · 05-28 18:24
康弘药业：KH631、KH658已完Ⅱ期和Ⅰ期入组
康弘药业（002773）披露二〇二五年度股东会决议公告，5月22日股价下跌1.35%
中金财经 · 05-22
康弘药业（002773）披露二〇二五年度股东会决议公告，5月22日股价下跌1.35%
股市必读：康弘药业（002773）5月21日董秘有最新回复
证券之星 · 05-22
股市必读：康弘药业（002773）5月21日董秘有最新回复
康弘药业(002773.SZ)：吡仑帕奈片获批上市
智通财经 · 05-21
康弘药业(002773.SZ)：吡仑帕奈片获批上市
康弘药业：基因治疗通过调控与修饰人体基因实现疾病防治
证券之星 · 05-21
康弘药业：基因治疗通过调控与修饰人体基因实现疾病防治
康弘药业：KH607已完成抑郁症临床Ⅱ期试验
证券之星 · 05-21
康弘药业：KH607已完成抑郁症临床Ⅱ期试验
康弘药业最新公告：子公司KH812眼内注射液获临床试验批准
证券之星 · 05-19
康弘药业最新公告：子公司KH812眼内注射液获临床试验批准
康弘药业：销售费用主要用于学术推广、临床研究、不良反应收集等
证券之星 · 05-19
康弘药业：销售费用主要用于学术推广、临床研究、不良反应收集等
康弘药业：KH631具有长期治疗nAMD的潜力
证券之星 · 05-19
康弘药业：KH631具有长期治疗nAMD的潜力
股市必读：康弘药业（002773）今年截至5月14日累计跌幅已超20%
证券之星 · 05-15
股市必读：康弘药业（002773）今年截至5月14日累计跌幅已超20%
股市必读：康弘药业（002773）5月8日董秘有最新回复
证券之星 · 05-11
股市必读：康弘药业（002773）5月8日董秘有最新回复
康弘药业：KH110处于临床III期阶段
证券之星 · 05-09
康弘药业：KH110处于临床III期阶段
康弘药业：截至2026年4月30日，公司股东户数约为3.82万户
证券之星 · 05-06
康弘药业：截至2026年4月30日，公司股东户数约为3.82万户
股市必读：康弘药业（002773）4月24日董秘有最新回复
证券之星 · 04-27
股市必读：康弘药业（002773）4月24日董秘有最新回复
康弘药业：4月23日召开业绩说明会，(天弘)、东北证券等多家机构参与
证券之星 · 04-24
康弘药业：4月23日召开业绩说明会，(天弘)、东北证券等多家机构参与
康弘药业最新公告：第一季度净利润同比下降23.13%
证券之星 · 04-22
康弘药业最新公告：第一季度净利润同比下降23.13%
康弘药业（002773）披露子公司获美国FDA准许开展KHN921注射液临床试验公告，4月20日股价上涨1.47%
证券之星 · 04-20
康弘药业（002773）披露子公司获美国FDA准许开展KHN921注射液临床试验公告，4月20日股价上涨1.47%
康弘药业KHN921获美国FDA批准开展肥厚型心肌病临床试验
美股速递 · 04-19
康弘药业KHN921获美国FDA批准开展肥厚型心肌病临床试验
康弘药业最新公告：子公司KHN921注射液获美国FDA临床试验许可
证券之星 · 04-19
康弘药业最新公告：子公司KHN921注射液获美国FDA临床试验许可
康弘药业（002773）披露使用8亿元自有资金购买结构性存款公告，4月7日股价下跌0.73%
证券之星 · 04-07
康弘药业（002773）披露使用8亿元自有资金购买结构性存款公告，4月7日股价下跌0.73%
加载更多
公司概况
公司名称：
成都康弘药业集团股份有限公司
所属行业：
医药制造业
上市日期：
2015-06-26
主营业务：
成都康弘药业集团股份有限公司的主营业务是药品（包括生物制品、中成药、化学药）和医疗器械（主要是眼科医疗器械）的研发、生产与销售。公司的主要产品是中成药、化学药、生物药、医疗器械。公司2025年荣获“环保诚信企业”和“无废工厂”称号。
发行价格：
13.62
{"stockData":{"symbol":"002773","market":"SZ","secType":"STK","nameCN":"康弘药业","latestPrice":21,"timestamp":1780038231000,"preClose":20.85,"halted":0,"volume":9053925,"delay":0,"changeRate":0.0072,"floatShares":687000000,"shares":921000000,"eps":1.1619,"marketStatus":"已收盘","change":0.15,"latestTime":"05-29 15:00:00","open":20.86,"high":21.33,"low":20.7,"amount":191000000,"amplitude":0.0302,"askPrice":21.03,"askSize":11,"bidPrice":21,"bidSize":262,"shortable":0,"etf":0,"ttmEps":1.1619,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780277400000},"marketStatusCode":5,"adr":0,"adjPreClose":20.85,"symbolType":"stock","openAndCloseTimeList":[[1780018200000,1780025400000],[1780030800000,1780038000000]],"highLimit":22.94,"lowLimit":18.77,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":921320954,"isCdr":false,"pbRate":2,"roa":"--","peRate":18.073845,"roe":"3.25%","epsLYR":1.26,"committee":0.013793,"marketValue":19348000000,"turnoverRate":0.0132,"status":0,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-06-01。","floatMarketCap":14422000000},"requestUrl":"/m/hq/s/002773","defaultTab":"news","newsList":[{"id":"2638066257","title":"康弘药业：KH631、KH658已完Ⅱ期和Ⅰ期入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2638066257","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638066257?lang=zh_cn&edition=full","pubTime":"2026-05-28 18:24","pubTimestamp":1779963858,"startTime":"0","endTime":"0","summary":"证券之星消息，康弘药业05月28日在投资者关系平台上答复投资者关心的问题。投资者提问：据2025年8月机构调研，公司预计2026年上半年可取得KH631和KH658的I期全部受试者一年安全性完整数据，目前该数据尚未正式对外发布，请问公司何时发布一期及二期的全部安全性、有效性完整数据？截至目前，基因治疗平台的眼科项目KH631、KH658，均已完成了中国的临床Ⅱ期入组和美国的临床Ⅰ期入组，预计将于今年底进入中国临床Ⅲ期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052800035588.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","LU2148510915.USD","BK0197","LU1064131003.USD","BK0239","BK0196","002773"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637431801","title":"康弘药业（002773）披露二〇二五年度股东会决议公告，5月22日股价下跌1.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637431801","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637431801?lang=zh_cn&edition=full","pubTime":"2026-05-22 17:59","pubTimestamp":1779443953,"startTime":"0","endTime":"0","summary":"近日，成都康弘药业集团股份有限公司发布《二〇二五年度股东会决议公告》。公告显示，公司于2026年5月21日召开二〇二五年度股东会，会议采用现场与网络投票相结合方式举行，出席会议股东共283人，代表股份648,045,507股，占公司有表决权股份总数的70.3383%。所有议案均获通过，无否决议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushiyaowen/20260522/32247302.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["002773","BK0239","LU1064130708.USD","BK0196","LU2148510915.USD","LU1064131003.USD","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637535965","title":"股市必读：康弘药业（002773）5月21日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2637535965","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637535965?lang=zh_cn&edition=full","pubTime":"2026-05-22 03:00","pubTimestamp":1779390038,"startTime":"0","endTime":"0","summary":"截至2026年5月21日收盘，康弘药业报收于21.47元，下跌0.88%，换手率1.54%，成交量10.6万手，成交额2.31亿元。成都康弘药业集团股份有限公司于2026年5月21日召开二〇二五年度股东会，会议采用现场与网络投票相结合方式举行，出席会议股东共283人，代表股份648,045,507股，占公司有表决权股份总数的70.3383%。所有议案均获通过，无否决议案。成都康弘药业集团股份有限公司收到国家药品监督管理局签发的吡仑帕奈片《药品注册证书》，批准该药品注册。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052200003451.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002773","LU2148510915.USD","LU1064130708.USD","LU1064131003.USD","BK0239","BK0197","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637333592","title":"康弘药业(002773.SZ)：吡仑帕奈片获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2637333592","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637333592?lang=zh_cn&edition=full","pubTime":"2026-05-21 19:44","pubTimestamp":1779363842,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 康弘药业(002773.SZ)发布公告，公司于近日收到国家药品监督管理局签发的吡仑帕奈片的《药品注册证书》(证书编号：2026S01622、2026S01623)，批准注册。吡仑帕奈片活性成分为吡仑帕奈，属于国家《麻醉药品和精神药品管理条例》规定的第二类精神药品。吡仑帕奈是突触后神经元离子型α-氨基-3-羟基-5-甲基-4-异恶唑丙酸(AMPA)谷氨酸受体的非竞争性拮抗剂。谷氨酸是中枢神经系统内主要的兴奋性神经递质，并参与神经元过度兴奋所引起的多种神经系统疾病。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444676.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002773","IPOS","BK0239","BK0196","LU1064130708.USD","LU2148510915.USD","LU1064131003.USD","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637138744","title":"康弘药业：基因治疗通过调控与修饰人体基因实现疾病防治","url":"https://stock-news.laohu8.com/highlight/detail?id=2637138744","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637138744?lang=zh_cn&edition=full","pubTime":"2026-05-21 18:48","pubTimestamp":1779360495,"startTime":"0","endTime":"0","summary":"投资者提问：公司领导您好，使用aav做为载体运送基因，已成为基因编辑治疗的主流，以美市场来看，很多基因治疗每次注射收费在2000万人民币，公司若能成功，收益将是巨大的。如您所说，基因治疗通过调控与修饰人体基因实现疾病防治，是当前全球生物医学领域的前沿核心技术。现阶段基于AAV载体的基因治疗多款产品已成功商业化落地，为患者带来了可供选择的新治疗方案。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100036857.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU2148510915.USD","002773","LU1064131003.USD","BK0196","BK0197","LU1064130708.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637638747","title":"康弘药业：KH607已完成抑郁症临床Ⅱ期试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2637638747","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637638747?lang=zh_cn&edition=full","pubTime":"2026-05-21 18:45","pubTimestamp":1779360317,"startTime":"0","endTime":"0","summary":"证券之星消息，康弘药业05月21日在投资者关系平台上答复投资者关心的问题。投资者提问：美国Vanotech有限公司今天宣布成功完成对成人重度抑郁障碍患者中KH607的2b期临床试验。KH607表现出快速、稳健和持续的抗抑郁效果。目前，KH607已完成抑郁症临床Ⅱ期试验，已显示出快速起效、疗效持续的特点，即将进入Ⅲ期临床试验。产后抑郁症的临床Ⅱ期试验正处于入组阶段。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052100036829.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0196","LU2148510915.USD","LU1064130708.USD","BK0197","LU1064131003.USD","BK0239","002773"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636722837","title":"康弘药业最新公告：子公司KH812眼内注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2636722837","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636722837?lang=zh_cn&edition=full","pubTime":"2026-05-19 18:19","pubTimestamp":1779185986,"startTime":"0","endTime":"0","summary":"康弘药业(002773.SZ)公告称，公司全资子公司康弘生物收到国家药监局签发的《药物临床试验批准通知书》，同意KH812眼内注射液开展用于新生血管(湿性)年龄相关性黄斑变性(nAMD)的临床试验。该药品为治疗用生物制品3.3类，能特异性结合VEGF-A和PIGF，抑制新生血管生成及炎症。公司提示，药品研发及审评结果存在不确定性，投资者需注意风险。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900035309.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","LU1064131003.USD","BK0196","002773","LU2148510915.USD","LU1064130708.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636587837","title":"康弘药业：销售费用主要用于学术推广、临床研究、不良反应收集等","url":"https://stock-news.laohu8.com/highlight/detail?id=2636587837","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636587837?lang=zh_cn&edition=full","pubTime":"2026-05-19 18:06","pubTimestamp":1779185165,"startTime":"0","endTime":"0","summary":"证券之星消息，康弘药业05月19日在投资者关系平台上答复投资者关心的问题。如果减少销售费用，营收是不是会面临断崖式下滑？公司2025年度实现营业收入4,585,133,789.58元，同比增长2.98%。公司的销售费用主要投入到学术推广、产品上市后的临床研究、不良反应收集、产品质量管理，员工的薪酬，渠道深耕及终端覆盖等。未来，公司持续强化经营管理，加强费用控制，提升管理效率和效益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900034675.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002773","LU1064131003.USD","BK0196","LU2148510915.USD","BK0197","LU1064130708.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636488858","title":"康弘药业：KH631具有长期治疗nAMD的潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2636488858","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636488858?lang=zh_cn&edition=full","pubTime":"2026-05-19 08:46","pubTimestamp":1779151572,"startTime":"0","endTime":"0","summary":"证券之星消息，康弘药业05月19日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，公司2026年明确BD为核心战略，KH631为最高价值管线： 1.相比同行RGX-314，KH631的长效性与安全性优势是否已成为与艾伯维等巨头谈判的核心筹码？KH631具有长期治疗nAMD的潜力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900009202.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002773","LU2148510915.USD","LU1064130708.USD","LU1064131003.USD","BK0239","BK0197","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635422347","title":"股市必读：康弘药业（002773）今年截至5月14日累计跌幅已超20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635422347","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635422347?lang=zh_cn&edition=full","pubTime":"2026-05-15 01:47","pubTimestamp":1778780832,"startTime":"0","endTime":"0","summary":"截至2026年5月14日收盘，康弘药业报收于22.48元，下跌2.73%，换手率1.23%，成交量8.44万手，成交额1.92亿元。当日关注点来自交易信息汇总：康弘药业股价连续3日下跌，5月14日收盘报22.48元，跌2.73%。该股已连续3日下跌，当年累计跌幅21.12%。前10个交易日主力资金累计净流出6424.05万元，股价累计下跌8.53%；融资余额累计增加5265.31万元，融券余量累计减少1.14万股。资金流向5月14日主力资金净流出2603.54万元，游资资金净流入88.89万元，散户资金净流入2514.65万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500001448.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","LU2148510915.USD","BK0197","LU1064131003.USD","BK0239","BK0196","002773"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634642425","title":"股市必读：康弘药业（002773）5月8日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2634642425","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634642425?lang=zh_cn&edition=full","pubTime":"2026-05-11 02:01","pubTimestamp":1778436075,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，康弘药业报收于24.23元，下跌1.46%，换手率1.15%，成交量7.87万手，成交额1.91亿元。KH110及KH631目前进展如何，近期是否有进展披露？二级市场股价受宏观经济、行业政策、市场情绪等多种因素共同影响。交易信息汇总资金流向5月8日主力资金净流出1325.01万元；游资资金净流出257.93万元；散户资金净流入1582.94万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100000968.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0197","002773","LU2148510915.USD","BK0239","LU1064131003.USD","LU1064130708.USD","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634495944","title":"康弘药业：KH110处于临床III期阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2634495944","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634495944?lang=zh_cn&edition=full","pubTime":"2026-05-09 08:48","pubTimestamp":1778287690,"startTime":"0","endTime":"0","summary":"证券之星消息，康弘药业05月09日在投资者关系平台上答复投资者关心的问题。KH110及KH631目前进展如何，近期是否有进展披露？二级市场股价受宏观经济、行业政策、市场情绪等多种因素共同影响。截至目前，KH110处于临床III期阶段，KH631眼用注射液处于中国临床II期阶段、美国临床I期阶段。由于药品从研发、临床试验、审评和审批的结果以及时间都具有一定的不确定性，敬请谨慎决策，注意投资风险。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050900004374.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","LU1064131003.USD","LU2148510915.USD","BK0197","002773","BK0196","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633900977","title":"康弘药业：截至2026年4月30日，公司股东户数约为3.82万户","url":"https://stock-news.laohu8.com/highlight/detail?id=2633900977","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633900977?lang=zh_cn&edition=full","pubTime":"2026-05-06 16:48","pubTimestamp":1778057297,"startTime":"0","endTime":"0","summary":"证券之星消息，康弘药业(002773)05月06日在投资者关系平台上答复投资者关心的问题。投资者提问：请问截至2026年4月30日公司的股东总数是多少？谢谢康弘药业回复：尊敬的投资者，您好!截至2026年4月30日，公司股东户数约为3.82万户。感谢您的关注与支持!以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600025272.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002773","LU1064130708.USD","BK0197","LU2148510915.USD","BK0196","BK0239","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630339836","title":"股市必读：康弘药业（002773）4月24日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2630339836","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630339836?lang=zh_cn&edition=full","pubTime":"2026-04-27 04:13","pubTimestamp":1777234389,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘，康弘药业报收于25.54元，下跌0.97%，换手率1.41%，成交量9.72万手，成交额2.47亿元。董秘最新回复投资者： 董秘您好，作为公司长期投资者，关注到公司近年持续使用大额资金购买理财产品，但上市以来从未实施股份回购。公司股价已连续9个月下行，投资者信心受到明显影响。截至目前，公司尚未收到回购、增持的相关计划通知。当日关注点来自交易信息汇总：4月24日主力资金净流出1152.51万元，显示主力短期态度偏空。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042700005788.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1064130708.USD","BK0197","LU2148510915.USD","002773","LU1064131003.USD","BK0239","BK0196"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629895035","title":"康弘药业：4月23日召开业绩说明会，(天弘)、东北证券等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2629895035","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629895035?lang=zh_cn&edition=full","pubTime":"2026-04-24 11:02","pubTimestamp":1776999746,"startTime":"0","endTime":"0","summary":"未来开发方向会有双抗双载荷甚至双抗多载荷等，并将适应症从肿瘤拓展至免疫等领域。康弘药业主营业务：药品和医疗器械的研发、生产与销售。康弘药业2026年一季报显示，一季度公司主营收入10.46亿元，同比下降12.7%；归母净利润3.07亿元，同比下降23.13%；扣非净利润3.05亿元，同比下降21.97%；负债率6.18%，投资收益-21.48万元，财务费用-1234.46万元，毛利率88.66%。该股最近90天内共有1家机构给出评级，买入评级1家。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400032871.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002773","BK0239","LU1064130708.USD","LU2148510915.USD","BK0028","BK0197","000686","BK0188","BK0183","BK0276","BK0196","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629049226","title":"康弘药业最新公告：第一季度净利润同比下降23.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629049226","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629049226?lang=zh_cn&edition=full","pubTime":"2026-04-22 20:41","pubTimestamp":1776861677,"startTime":"0","endTime":"0","summary":"康弘药业(002773.SZ)公告称，2026年第一季度实现营业收入10.46亿元，同比下降12.70%；归属于上市公司股东的净利润为3.07亿元，同比下降23.13%。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200050891.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002773"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628745035","title":"康弘药业（002773）披露子公司获美国FDA准许开展KHN921注射液临床试验公告，4月20日股价上涨1.47%","url":"https://stock-news.laohu8.com/highlight/detail?id=2628745035","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628745035?lang=zh_cn&edition=full","pubTime":"2026-04-20 17:17","pubTimestamp":1776676666,"startTime":"0","endTime":"0","summary":"截至2026年4月20日收盘，康弘药业报收于27.01元，较前一交易日上涨1.47%，最新总市值为248.85亿元。该股当日开盘26.62元，最高27.88元，最低26.39元，成交额达4.91亿元，换手率为2.65%。近日，康弘药业披露《关于子公司获得美国FDA准许开展临床试验的公告》。公告显示，公司子公司成都弘基生物科技有限公司收到美国食品药品管理局邮件，获准KHN921注射液在美国开展临床试验。该产品的研发及临床进展存在不确定性，提醒投资者注意投资风险。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042000023760.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002773","BK0239","LU1064130708.USD","LU2148510915.USD","BK0197","BK0196","LU1064131003.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189981730","title":"康弘药业KHN921获美国FDA批准开展肥厚型心肌病临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=1189981730","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189981730?lang=zh_cn&edition=full","pubTime":"2026-04-19 17:12","pubTimestamp":1776589938,"startTime":"0","endTime":"0","summary":"康弘药业集团宣布，其创新药物KHN921已获得美国食品药品监督管理局（FDA）的临床试验批准，将用于治疗肥厚型心肌病。这一重要监管突破标志着该药物正式进入国际临床开发阶段。\n肥厚型心肌病是一种常见遗传性心脏病，KHN921作为公司研发管线中的重要品种，此次获批彰显了其创新潜力。临床试验的启动将为后续全球市场拓展奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","LU1064131003.USD","LU1064130708.USD","002773","BK0196","LU2148510915.USD","BK0197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628766723","title":"康弘药业最新公告：子公司KHN921注射液获美国FDA临床试验许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2628766723","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628766723?lang=zh_cn&edition=full","pubTime":"2026-04-19 16:30","pubTimestamp":1776587414,"startTime":"0","endTime":"0","summary":"康弘药业(002773.SZ)公告称，公司子公司成都弘基生物科技有限公司近日收到美国食品药品监督管理局(FDA)邮件，准许其自主研发的KHN921注射液在美国开展临床试验。该药品为AAV基因治疗产品，适应症为MYBPC3基因突变相关的肥厚型心肌病(HCM)。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026041900006305.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0197","002773","LU1064131003.USD","BK0196","LU1064130708.USD","LU2148510915.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625120931","title":"康弘药业（002773）披露使用8亿元自有资金购买结构性存款公告，4月7日股价下跌0.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2625120931","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625120931?lang=zh_cn&edition=full","pubTime":"2026-04-07 18:13","pubTimestamp":1775556796,"startTime":"0","endTime":"0","summary":"截至2026年4月7日收盘，康弘药业报收于28.43元，较前一交易日下跌0.73%，最新总市值为261.93亿元。该股当日开盘28.63元，最高29.07元，最低27.92元，成交额达3.45亿元，换手率为1.77%。近日，康弘药业披露《关于使用自有资金购买理财产品的公告》。公告显示，公司使用闲置自有资金8亿元人民币，向中国银行成都武侯支行购买了名为“人民币结构性存款”的保本浮动收益型理财产品，产品期限为47天，自2026年4月3日起算，到期日为2026年5月20日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040700025189.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002773","LU2148510915.USD","BK0196","LU1064131003.USD","LU1064130708.USD","BK0239","BK0197"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1780167411624,"stockEarnings":[{"period":"1week","weight":-0.0085},{"period":"1month","weight":-0.1559},{"period":"3month","weight":-0.2818},{"period":"6month","weight":-0.3333},{"period":"1year","weight":-0.2758},{"period":"ytd","weight":-0.2993}],"compareEarnings":[{"period":"1week","weight":-0.0108},{"period":"1month","weight":-0.0095},{"period":"3month","weight":-0.0227},{"period":"6month","weight":0.0463},{"period":"1year","weight":0.2096},{"period":"ytd","weight":0.0251}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"成都康弘药业集团股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"38200人(较上一季度增加1.33%)","perCapita":"17978股","listingDate":"2015-06-26","address":"四川省成都市金牛区蜀西路108号","registeredCapital":"92132万元","survey":" 成都康弘药业集团股份有限公司的主营业务是药品（包括生物制品、中成药、化学药）和医疗器械（主要是眼科医疗器械）的研发、生产与销售。公司的主要产品是中成药、化学药、生物药、医疗器械。公司2025年荣获“环保诚信企业”和“无废工厂”称号。","listedPrice":13.62},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康弘药业(002773)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康弘药业(002773)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康弘药业,002773,康弘药业股票,康弘药业股票老虎,康弘药业股票老虎国际,康弘药业行情,康弘药业股票行情,康弘药业股价,康弘药业股市,康弘药业股票价格,康弘药业股票交易,康弘药业股票购买,康弘药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康弘药业(002773)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康弘药业(002773)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}